Related references
Note: Only part of the references are listed.Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer
Karen M. Gallegos et al.
FRONTIERS IN ONCOLOGY (2021)
Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness
Jankiben R. Patel et al.
ONCOLOGY LETTERS (2021)
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer
Balazs Gyorffy
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cristina Nieto-Jimenez et al.
CANCER LETTERS (2020)
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2020)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
A methylation-phosphorylation switch determines Plk1 kinase activity and function in DNA damage repair
Weizhe Li et al.
SCIENCE ADVANCES (2019)
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis
Zheng Fu et al.
CANCERS (2017)
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Rosie Elizabeth Ann Gutteridge et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition
Mika Pietilae et al.
SCIENTIFIC REPORTS (2016)
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
F. de Braud et al.
ANNALS OF ONCOLOGY (2015)
Spherical Cancer Models in Tumor Biology
Louis-Bastien Weiswald et al.
NEOPLASIA (2015)
Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer
Christiana S. Kappler et al.
MOLECULAR ONCOLOGY (2015)
Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
Virginie Maire et al.
CANCER RESEARCH (2013)
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Balazs Gyoerffy et al.
ENDOCRINE-RELATED CANCER (2012)
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells
Kaiji Hu et al.
BREAST CANCER RESEARCH (2012)
Plk1-Targeted Small Molecule Inhibitors: Molecular Basis for Their Potency and Specificity
Ravichandran N. Murugan et al.
MOLECULES AND CELLS (2011)
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Balazs Gyoerffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
G Dontu et al.
GENES & DEVELOPMENT (2003)
Share Paper
